Testing sacituzumab tirumotecan for triple-negative breast cancer that has spread to the brain
Official title: Sac-TMT for Active TNBC Brain Metastases
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This trial is testing a drug called sacituzumab tirumotecan in people whose triple-negative breast cancer has spread to the brain.
Read our full plain-language summary
What the trial team says
This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of every 28-day cycle until disease progression, unacceptable toxicities, consent withdrawal, or death.
Key facts
- Registry number
- NCT07458113
- Stage of testing
- Phase 2
- Conditions studied
- Metastatic Triple Negative Breast Cancers
Where it is running
This trial lists 1 site.
-
Connecticut
- Yale University (New Haven)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.